Tevogen Bio Signs Letter of Intent to Evaluate MSO Acquisition
Tevogen Bio signs letter of intent to evaluate MSO acquisition as part of strategy to reach $100 million in...
GENFIT Q1 2026 Royalties Jump 243% on Ipsen’s Iqirvo Sales
GENFIT's Q1 2026 royalties surged 243% as Ipsen's Iqirvo sales reached €78.8M, triggering a $20M milestone payment ahead of...
Humacyte’s Symvess Gains VA Contract Covering 170 Hospitals
Humacyte's Symvess gains VA contract covering 170 hospitals, collapsing typical procurement timelines through centralized approval.
Liminatus Pharma to Acquire InnocsAI for $320M in Stock Deal
Liminatus Pharma InnocsAI $320M stock deal brings IBC101 CAR-T for relapsed/refractory DLBCL into development pipeline.
PharmAla Licenses MDMA Therapeutic ALA-002 to Jupiter Neurosciences for $100M+
PharmAla licenses MDMA therapeutic ALA-002 to Jupiter Neurosciences in $100M+ deal featuring novel chemical entity status and FDA exclusivity...
Humacyte’s Symvess Secures VA Strategic Acquisition Contract
Humacyte's Symvess secures VA Strategic Acquisition Center contract, bypassing hospital-by-hospital approval delays across 170 VA facilities.
Quince Acquires Orphai, Raises $187M for LAM-001 Pulmonary Pipeline
Quince acquires Orphai and raises $187M to advance LAM-001 pulmonary pipeline through Phase 2b trials in PH-ILD, BOS, and...
Oorja Bio Raises $30M Series A for IPF Drug ORJ-001
Oorja Bio raises $30M Series A to advance ORJ-001, a novel subcutaneous peptide targeting upstream epithelial dysfunction in idiopathic...
PharmAla Licenses ALA-002 U.S. Rights to Jupiter Neurosciences for $100M
PharmAla licenses ALA-002 U.S. rights to Jupiter Neurosciences for $100M, with NCE-protected MDMA formulation advancing through regulatory pathway.
SERB Acquires European, MENA Rights to Idefirix From Hansa for €115M
SERB acquires Idefirix European and MENA rights from Hansa for €115M, gaining exclusive access to a rare transplant immunosuppressant.